|
|
 |
News Article |
| First European Patent Granted |
October 12, 2005
|
The Resonance Health Group is pleased to announce that it has been granted its first patent in the important European market.
European Patent 1,218,766 describes and protects the core invention underlying the FerriScan® test for the non-invasive measurement of liver iron concentration.
This patent is the European equivalent to the US Patent 6,605,943 which was granted in 2003 and which is also being prosecuted in several other jurisdictions.
"The granting of the European Patent for the cornerstone of our technology platform confirms its novelty and secures our monopoly in the large European market" said Resonance Health Managing Director Dr James Williams. "The combination of having granted patents, completed major regulatory clearances and being first to market
strengthens Resonance Health's position as the leader in the commercial application of MRI for the non-invasive measurement of liver iron concentration" he continued.
Resonance Health is also prosecuting a second patent family which further expands the company's technology platform, and, in addition, continues various Research & Development programs which have the potential to further expand the scope of the company's intellectual property assets.
Following the completion of the acquisition of Inner Vision Biometrics Pty Ltd in May 2005, Resonance Health owns, royalty free, 100% of the intellectual property assets relating to the FerriScan test. |
View all news articles |
|
